Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by HAGOP M KANTARJIAN and APOSTOLIA MARIA TSIMBERIDOU.
HAGOP M KANTARJIAN
Connection Strength
2.506
APOSTOLIA MARIA TSIMBERIDOU
  1. The role of gemtuzumab ozogamicin in acute leukaemia therapy. Br J Haematol. 2006 Feb; 132(4):398-409.
    View in: PubMed
    Score: 0.269
  2. A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2014 Oct; 14(5):395-400.e1.
    View in: PubMed
    Score: 0.117
  3. Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):568-74.
    View in: PubMed
    Score: 0.112
  4. Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer. 2009 Jan 15; 115(2):373-80.
    View in: PubMed
    Score: 0.082
  5. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol. 2009 Feb 20; 27(6):904-10.
    View in: PubMed
    Score: 0.082
  6. The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Cancer. 2008 Oct 01; 113(7):1605-13.
    View in: PubMed
    Score: 0.081
  7. Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia. Cancer. 2008 Sep 15; 113(6):1370-8.
    View in: PubMed
    Score: 0.081
  8. The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients. Clin Cancer Res. 2008 Feb 01; 14(3):721-30.
    View in: PubMed
    Score: 0.077
  9. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2008 Jan 10; 26(2):196-203.
    View in: PubMed
    Score: 0.077
  10. Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center. J Clin Oncol. 2007 Oct 10; 25(29):4648-56.
    View in: PubMed
    Score: 0.076
  11. Anaplastic large cell lymphoma with involvement of the pancreas presenting as panniculitis in a patient with a history of acute myeloid leukemia--case report and review of the literature. Haematologica. 2006 Dec; 91(12 Suppl):ECR55.
    View in: PubMed
    Score: 0.071
  12. Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide? Leuk Lymphoma. 2006 Nov; 47(11):2282-8.
    View in: PubMed
    Score: 0.071
  13. Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. Cancer. 2006 Sep 15; 107(6):1294-302.
    View in: PubMed
    Score: 0.070
  14. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer. 2006 Jul 01; 107(1):125-35.
    View in: PubMed
    Score: 0.069
  15. Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series. Leuk Lymphoma. 2006 Jun; 47(6):1062-8.
    View in: PubMed
    Score: 0.069
  16. Granulocyte colony stimulating factor administration associated with cerebral hemorrhage in acute promyelocytic leukemia. Leukemia. 2006 Aug; 20(8):1452-3.
    View in: PubMed
    Score: 0.069
  17. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol. 2006 May 20; 24(15):2343-51.
    View in: PubMed
    Score: 0.069
  18. Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid. Blood. 2005 Feb 01; 105(3):1366-7.
    View in: PubMed
    Score: 0.063
  19. Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies. Leuk Res. 2004 Sep; 28(9):991-4.
    View in: PubMed
    Score: 0.061
  20. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. Cancer. 2004 Jun 15; 100(12):2583-91.
    View in: PubMed
    Score: 0.060
  21. Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature. Leuk Res. 2004 Jun; 28(6):657-60.
    View in: PubMed
    Score: 0.060
  22. Anti-B4 blocked ricin post chemotherapy in patients with chronic lymphocytic leukemia--long-term follow-up of a monoclonal antibody-based approach to residual disease. Leuk Lymphoma. 2003 Oct; 44(10):1719-25.
    View in: PubMed
    Score: 0.057
  23. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res. 2003 Oct; 27(10):893-7.
    View in: PubMed
    Score: 0.057
  24. Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol. 2003 Dec; 52(6):449-52.
    View in: PubMed
    Score: 0.057
  25. Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy. Leukemia. 2003 Jun; 17(6):1100-3.
    View in: PubMed
    Score: 0.056
  26. Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders. Cancer Chemother Pharmacol. 2003 Sep; 52(3):229-34.
    View in: PubMed
    Score: 0.056
  27. Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment. Leuk Res. 2003 May; 27(5):375-80.
    View in: PubMed
    Score: 0.055
  28. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer. 2003 Apr 01; 97(7):1711-20.
    View in: PubMed
    Score: 0.055
  29. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer. 2003 Mar 15; 97(6):1481-7.
    View in: PubMed
    Score: 0.055
  30. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med. 2023 01; 29(1):115-126.
    View in: PubMed
    Score: 0.054
  31. Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies. Cancer Chemother Pharmacol. 2002 Sep; 50(3):237-42.
    View in: PubMed
    Score: 0.053
  32. Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders. Leuk Lymphoma. 2002 Apr; 43(4):767-72.
    View in: PubMed
    Score: 0.051
  33. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma. 2007 Oct; 48(10):1931-9.
    View in: PubMed
    Score: 0.019
  34. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. Leuk Res. 2005 Jun; 29(6):649-52.
    View in: PubMed
    Score: 0.016
  35. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia. 2003 Nov; 17(11):2101-6.
    View in: PubMed
    Score: 0.014
  36. Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leuk Res. 2003 Oct; 27(10):887-91.
    View in: PubMed
    Score: 0.014
  37. Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia. Leuk Res. 2003 Apr; 27(4):301-4.
    View in: PubMed
    Score: 0.014
  38. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemother Pharmacol. 2003 Jan; 51(1):87-90.
    View in: PubMed
    Score: 0.013
  39. Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. Cancer Chemother Pharmacol. 2002 Dec; 50(6):497-500.
    View in: PubMed
    Score: 0.013
  40. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. Ann Oncol. 2000 Jan; 11(1):69-72.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.